SELECT * FROM `stock_list` where symbol='FAB' AND exchange = 'LSE' limit 0,1 SELECT * FROM `stock_list` where symbol='FAB' AND exchange = 'LSE' limit 0,1 SELECT * FROM `stock_list` WHERE `symbol` = "FAB" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
Fusion Antibodies (LSE:FAB) Book Value per Share
Fusion Antibodies's book value per share for the quarter that ended in Sep. 2023 was £0.02.
During the past 12 months, Fusion Antibodies's average Book Value Per Share Growth Rate was -75.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -41.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -27.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Fusion Antibodies was 234.00% per year. The lowest was -41.80% per year. And the median was 13.40% per year.
Fusion Antibodies's current price is £0.03225. Its book value per share for the quarter that ended in Sep. 2023 was £0.02. Hence, today's PB Ratio of Fusion Antibodies is 0.75.
During the past 9 years, the highest P/B Ratio of Fusion Antibodies was 27.66. The lowest was 0.74. And the median was 3.61.
Fusion Antibodies Book Value per Share Historical Data
The historical data trend for Fusion Antibodies's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fusion Antibodies's Book Value per Share
For the Biotechnology subindustry, Fusion Antibodies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's PB Ratio falls into.
Fusion Antibodies Book Value per Share Calculation
Fusion Antibodies's Book Value Per Share for the fiscal year that ended in Mar. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Fusion Antibodies (LSE:FAB) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Fusion Antibodies Book Value per Share Related Terms
Thank you for viewing the detailed overview of Fusion Antibodies's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:FAB has been successfully added to your 